Not peer-reviewed Table 1. Selected studies relevant to risk-based breast cancer screening Study Design Population Risk factors used Main outcome Key finding Registration Esserman et al., 2026 (WISDOM)1 Randomized clinical trial 28,372 women, United States Clinical risk factors, breast density, PRS, 9 susceptibility genes Stage ≥IIB breast cancer Noninferior to annual screening; fewer mammograms but no reduction in biopsy rates NCT02620852 Roux et al., 2022 (MyPeBS protocol)7 Randomized clinical trial (ongoing) ∼85,000 women, Europe and Israel Clinical risk factors, breast density, PRS Advanced breast cancer incidence Ongoing evaluation of risk-stratified screening NCT03672331 Roux et al., 2025 (MyPeBS ancillary study)8 Cross-sectional survey of healthcare professionals 198 professionals from 6 countries Risk communication and implementation practices Acceptability of risk-based screening Broad support for risk-based screening; concerns regarding training and implementation NCT03672331 Pashayan et al., 20182 Modeling study Simulated population Risk-stratified screening Benefit-toharm ratio Predicted improved efficiency of screening Not applicable Trentham-Dietz et al., 20163 CISNET modeling study Women ≥50 years Breast density and clinical risk factors Screening outcomes Extended intervals feasible in lowerrisk women Not applicable van Ravesteyn et al., 20214 CISNET modeling study Low-risk women Risk-based interval assignment Harms and benefits Fewer false-positive findings with less intensive screening Not applicable Bakker et al., 2019 (DENSE)5 Randomized trial Women with extremely dense breasts Breast density Interval cancer rate Supplemental MRI reduced interval cancers NTR2499 Saadatmand et al., 2019 (FaMRIsc)6 Randomized trial Women with familial risk Family history Stage at diagnosis MRI improved early detection NTR3689 CISNET, Cancer Intervention and Surveillance Modeling Network; DENSE, Dense Tissue and Early Breast Neoplasm Screening; FaMRIsc, Familial MRI Screening; MRI, magnetic resonance imaging; MyPeBS, My Personal Breast Screening; NCT, National Clinical Trial number; NTR, Netherlands Trial Register; PRS, polygenic risk score; WISDOM, Women Informed to Screen Depending on Measures of Risk.